Relationship between osteonecrosis of the jaw and bisphosphonate treatment;Povezanost osteonekroze čeljusti i terapije bisfosfonatima

Arhiv za Higijenu Rada i Toksikologiju

Volumn 61, Issue 3, 2010, Pages 371-380

  Badel, Tomislav ^a   Keros, Jadranka ^a   Krapac, Ladislav ^b   Pavičin, Ivana ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Poliklinika za reumatske bolesti   (Croatia)

Author keywords

bisphosphonates; mandible; maxilla; oral health; osteoclasts; osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; NITROGEN; PAMIDRONIC ACID; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ANTIANGIOGENIC ACTIVITY; CYTOTOXICITY; DRUG POTENCY; EPIDEMIOLOGICAL DATA; HEREDITY; HUMAN; JAW OSTEONECROSIS; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOPOROSIS; REVIEW; TREATMENT DURATION; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; JAW DISEASE; PATHOPHYSIOLOGY;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 77957127462     PISSN: 00041254     EISSN: None     Source Type: Journal    
DOI: 10.2478/10004-1254-61-2010-2032     Document Type: Review

References (71)

1. Almazrooa SA, Woo S-B. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw. J Am Dent Assoc 2009;140:864-875
2. Southerland JH, Patton LL. Management of spontaneous osteoradionecrosis: A case report. Spec Care Dentist 1993;13:200-204
3. Rainsford M. Osteomyelitis of the Jaw. Proc R Soc Med 1945;38:452-455
4. Cupar I. Kirurgija glave i vrata. Knjiga prva. Zagreb: JAZU; 1975.
5. Uglešic V, Batagin M. Difuzni sklerozirajuci osteomijelitis gornje celjusti: Pregled literature i prikaz slucaja. Acta Stomatol Croat 1988;22:297-304.
6. Bernier S, Clermont S, Maranda G, Turcotte JY. Osteomyelitis of the jaws. J Can Dent Assoc 1995;61:441- 2, 445-448
7. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-689
8. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaw: History, etiology, prevention, and treatment. Hanover Park (IL): Quintessence Publishing Co., Inc.; 2007.
9. Žuškin E, Mustajbegovic J, Vlasta Deckovic-Vukres, Zavalic M, Bogadi-Šare A, Poplašen-Orlovac D. Prohic A, Bubaš M. Prepoznavanje potrebe zdravstvene skrbi o radnicima tijekom povijesti. Arh Hig Rada Toksikol 2006;57:201-212
10. Myers ML, McGlothlin JD. Matchmakers' "phossy jaw" eradicated. Am Ind Hyg Assoc J 1996;57:330-332
11. Miles AE. Phosphorus necrosis of the jaw: "phossy jaw". Br Dent J 1972;133:203-206
12. Durakovic Z, i sur. Klinicka toksikologija. Zagreb: Grafos; 2000.
13. US Department of Health and Human Services, Public Health Service, and Agency for Toxic Substances and Disease Registry. Toxicological Profile for White Phosphorus 1997 [pristup 27. prosinca 2009] Dostupno na http://www.atsdr. cdc.gov/toxprofi les/tp103.pdf.
14. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
15. Wong YK, Cheng JC. Bisphosphonate-related osteonecrosis of the jaws - Report of 2 cases and strategies on prevention and management. Quintessence Int 2008;39:195-201.
16. Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14:158-170
17. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009;122:22-32.
18. Curkovic B, Grazio S, Babic-Naglic D, Anic B, Vlak T, Hanih M. Preporuke Hrvatskog reumatološkog društva u prevenciji, dijagnostici i lijecenju postmenopauzalne osteoporoze. Reumatizam 2008;55:26-30.
19. Dhillon S, Lyseng-Williamson KA. Zoledronic acid: A review of its use in the management of bone metastases of malignancy. Drugs 2008;68:507-534
20. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
21. Favus MJ, Vokes TJ. Paget disease and other dysplasias of bone. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, urednici. Harrison's principles of internal medicine. 16th ed. Berkshire: McGraw-Hill; 2004. Chapter 334.
22. Gutt R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: Science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104;186-193
23. Dannemann C, Grötz KW, Twahlen R. Die Bisphosphonatassoziierte Osteonekrose der Kiefer. Schweiz Monatschr Zahnmed 2008;118:113-118
24. Reid IR. Osteonecrosis of the jaw - who gets it, and why? Bone 2009;44:4-10.
25. Abu-Id MH, Warnke PH, Gottschalk J, Springer I, Wiltfang J, Acil Y, Russo PA, Kreusch T. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 2008;36:95-103.
26. Mavrokkoki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65:415-423
27. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-5362
28. Walter C, Grötz KA, Kašaj A, Albrich S, Schmidt M, Nauroth B, Al-Nawas B. A prevalence of bisphosphonate associated osteonecrosis of the jaws in breast cancer patients. Acta Stomatol Croat 2009;43:271-278
29. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009;115:1631-1637
30. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate- associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-1072
31. Hoffmann F, Jung TI, Felsenberg D, Glaeske G. Pattern of intravenous bisphosphonate use in outpatient care in Germany. Pharmacoepidemiol Drug Saf 2008;17:896-903.
32. Khan AA, S?dor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-490
33. Ficarra G, Beninati F. Bisphosphonate-related osteonecrosis of the jaws: An update on clinical, pathological and management aspects. Head Neck Pathol 2007;1:132-140
34. Sambrook PN, Ebeling P. Osteonecrosis of the jaw. Curr Rheumatol Reports 2008;10:97-101.
35. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonates-induced jaw osteonecrosis. Oral Dis 2008;14:277-285
36. Han ZH, Palnitkar S, Rao DS, Nelson D, Parfi tt AM. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: Implication for mechanisms of bone loss. J Bone Miner Res 1997;12:498-508. (Pubitemid 27155209)
37. Mashiba T, Turner CH, Hirano T, Forwood MR, Jacob DS, Johnston CC, Burr DB. Effects of high-dose etidronate treatment on micromechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 2001;29:271-278
38. Brown HK, Holen I. Anti-tumour effects of bisphosphonates - what have we learned from in vivo models? Curr Cancer Drug Targets 2009;9:807-823
39. Hansen T, Kunkel M, Weber A. Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160
40. Bosak A. Organofosforni spojevi: Klasifi kacija i reakcije s enzimima. Arh Hig Rada Toksikol 2006;57:445-457
41. Rainer Ž. Statini u primarnoj i sekundarnoj prevenciji koronarne bolesti. Medicus 2003;12:85-90.
42. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanism of action of bisphosphonates: Current status. Clin Cancer Res 2006;12(Suppl 20):6223S-30S.
43. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanism of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 2008;19:733-759
44. Žlender V. Apoptoza - programirana smrt stanice. Arh Hig Rada Toksikol 2003;54:267-274
45. Boranic M. Psihoneuroendokrini cinitelji i apoptoza. Acta Med Croat 2009;63:27-31.
46. Burr DB, Allen MR. Mandibular necrosis in beagle dogs reated with bisphosphonates. Orthod Craniofac Res 2009;12:221-228
47. Boyce BF, Yao Z, Zhang Q, Guo R, Lu Y, Schwarz EM, Xing L. New roles for osteoclasts in bone. Ann NY Acad Sci 2007;1116:245-254
48. Bell NH. RANK ligand and the regulation of skeletal remodeling. J Clin Invest 2003;111:1120-1122
49. Gómez Font R, Martínez García ML, Olmos Martínez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal 2008;13: E318-24 [pristup 24. veljace 2010]. Dostupno na http://www. medicinaoral.com/medoralfree01/v13i5/ medoralv13i5p318. pdf.
50. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008;42:848-860
51. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaw: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575
52. Hall V. Actinomyces - Gathering evidence of human colonization and infection. Anaerobe 2008;14:1-7.
53. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofi lms: A common cause of persistent infections. Science 1999;284:1318-1322
54. Belibasakis GN, Bostanci N, Hashim A, Johansson A, Aduse- Opoku J, Curtis MA, Hughes FJ. Regulation of RANKL and OPG gene expression in human gingival fi broblasts and periodontal ligament cells by Porphyromonas gingivalis: A putative role of the Arg-gingipains. Microb Pathog 2007;43:46-53.
55. Yarom N, Yarom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporosis Int 2007;18:1363-1370
56. Grbic JT, Landesberg R, Lin SQ, Mesenbrink P, Reid IR, Leung PC, Casas N, Recknor CP, Hua Y, Delmas PD, Eriksen EF. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008;139:32-40.
57. Green JR. Bisphosphonates: Preclinical review. Oncologist 2004;9(Suppl 4):3-13.
58. Takagi Y, Sumi Y, Harada A. Osteonecrosis associated with short-term oral administration of bisphosphonate. J Prosthet Dent 2009;101:289-291
59. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-495
60. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008;42:848-860
61. Cornish J, Bava U, Reid I. Bisphosphonate-treated bone is toxic to epithelial cells-mechanism of ONJ? Bone 2009;44(Suppl 2):S283.
62. De Gobbi M, Viprakasit V, Hughes JR Fisher C, Buckle VJ, Ayyub H, Gibbons RJ, Vernimmen D, Yoshinaga Y, de Jong P, Cheng JF, Rubin EM, Wood WG, Bowden D, Higgs DR. A regulatory SNP causes a human genetic disease bycreating a new transcriptional promoter. Science 2006;312:1215-1217
63. Sarasquete ME, González M, San Miguel JF, García-Sanz R. Bisphosphonate-related osteonecrosis: Genetic and acquired risk factors. Oral Dis 2009;15:382-387
64. Viccica G, Vignali E, Marcocci C. Role of the cholesterol biosynthetic pathway in osteoblastic differentiation. J Endocrinol Invest 2007;30(Suppl 6):8-12.
65. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009;67:159-161
66. Yarom N, Lazarovici TS, Elad S. Oral bisphosphonaterelated osteonecrosis of the jaw: Incidence, clinical features, prevention, and treatment recommendations. Clinic Rev Bone Miner Metab 2010;8:27-31.
67. Eckert AW, Maurer P, Meyer L, Kriwalsky MS, Rohrberg R, Schneider D, Bilkenroth U, Schubert J. Bisphosphonaterelated jaw necrosis - Severe complication in Maxillofacial surgery. Cancer Treat Rev 2007;33:58-63.
68. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(Suppl 1):96-106.
69. Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010;59:181-213.
70. Cesar A, Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
71. Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 2009;15:88-92.